Precision for Medicine

The deal provides Precision for Medicine with a proprietary PCR-based technology that amplifies and detects euchromatic DNA expressed exclusively by cell types of interest.

The deal joins Precision for Medicine's suite of biomedical research tools and services with ACT Oncology's expertise in clinical study design and execution.

PATH is designed to help users combine and use clinical and genomic information to stratify patients as part of efforts to develop more tailored therapies.

CEOs at four of the five leading mass spec firms saw their total compensation dip last year, according to information provided in their proxy statements, with Bill Sullivan at Agilent taking the biggest hit, a 39 percent drop from his 2007 earnings. Meanwhile, Frank Laukien at Bruker received an 80 percent upgrade in 2008.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.